Lendlease – Challenging Year

Posted on | by Leon Hinde

Lendlease has warned of a challenging year to come as COVID-19 puts a dampener on development and construction globally.

FY21 net profit after tax of $377 million was in line with the company’s guidance, largely due to divesting its loss-making engineering and services.

We expect to see an improvement in earnings towards the end of FY22.

CIMIC – Buy Call Options

Posted on | by Leon Hinde

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Buy Dec $20 call options as a stock replacement strategy. For more detail, please call 1300 614 002.

Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Downer EDI – Buy

Posted on | by Leon Hinde

DOW:ASX is now under Algo Engine buy conditions. The company has guided towards double-digit earnings growth into FY22 & FY23.

Downer EDI has found support and buying interest has increased above $5.00.

12/8 Update: Downer EDI has now rallied from $5.00 to $5.80.

Crown – Add to Watchlist

Posted on | by Leon Hinde

The current weakness in the Crown share price could be a buying opportunity. It’s unlikely that the current COVID-related operational impacts are going to deter the interested parties who have put forward takeover offers.

Continue to track the CWN share price and wait for a cross above the 10-day average.

12/8 Update: CWN is now trading above the 10 day average.